WHO ICTRP trial
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
CTRI/2009/091/000752 · Clinical Trials Registry India (CTRI) · Not Recruiting
Key facts
| Trial ID | CTRI/2009/091/000752 |
|---|---|
| Public title | Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression |
| Scientific title | A 24-Week, Flexible-Dose, Open-label Extension Study of Lurasidone for the Treatment of Bipolar I Depression. |
| Primary sponsor | Sunovion Pharmaceuticals Inc |
| Registry | Clinical Trials Registry India (CTRI) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase 3 |
| Countries | India;Czech Republic;France;Germany;Poland;Romania;Russian Federation;South Africa;Ukraine;United States of America |
| Conditions | Health Condition 1: null- Bipolar I depression Health Condition 2: F318- Other bipolar disorders |
| Interventions | Intervention1: lurasidone: Lurasidone 20, 40, 60, 80, 100 or 120 mg/day, orally, once daily in the evening, with a meal or within 30 minutes after eating, for 6 weeks. Lurasidone dosing will be initiated at 20 mg/day for Days 1-3 and 40… |
| Registration date | Oct 14, 2009 |
| Target size | 460 |
| Secondary IDs | D1050256;NCT00868959 |
| Registry page | ctri.nic.in |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: